Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by General American Investors Co. Inc.

General American Investors Co. Inc. lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,876 shares of the biopharmaceutical company’s stock after selling 2,700 shares during the period. General American Investors Co. Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,485,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sachetta LLC increased its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter worth about $26,000. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Finally, Family Firm Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 0.3 %

NASDAQ REGN traded up $2.35 during trading on Thursday, reaching $819.00. 13,556 shares of the company’s stock were exchanged, compared to its average volume of 518,566. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The company’s fifty day simple moving average is $1,035.92 and its 200-day simple moving average is $1,038.36. The firm has a market capitalization of $90.29 billion, a PE ratio of 20.21, a P/E/G ratio of 3.17 and a beta of 0.15.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.48% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently commented on REGN shares. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Royal Bank of Canada lowered their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday. Finally, Evercore ISI dropped their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,092.62.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.